The 10-second takeaway
For the quarter ended Dec. 31 (Q4), Antares Pharma beat expectations on revenues and met expectations on earnings per share.
Compared to the prior-year quarter, revenue improved significantly and GAAP earnings per share improved to zero.
Gross margins contracted, operating margins increased, and net margins improved.
Antares Pharma reported revenue of $5.4 million. The four analysts polled by S&P Capital IQ wanted to see revenue of $4.9 million on the same basis. GAAP reported sales were 65% higher than the prior-year quarter's $3.3 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at $0. The four earnings estimates compiled by S&P Capital IQ predicted $0 per share. GAAP EPS contracted to zero from the prior-year quarter's -$0.02.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 60.5%, 1,260 basis points worse than the prior-year quarter. Operating margin was -3.0%, 3,430 basis points better than the prior-year quarter. Net margin was -2.8%, 3,680 basis points better than the prior-year quarter.
Next quarter's average estimate for revenue is $5.1 million. On the bottom line, the average EPS estimate is $0.
Next year's average estimate for revenue is $24.2 million.
The stock has a four-star rating (out of five) at Motley Fool CAPS, with 158 members out of 166 rating the stock outperform, and eight members rating it underperform. Among 21 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 18 give Antares Pharma a green thumbs-up, and three give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Antares Pharma is outperform, with an average price target of $3.
The healthcare investing landscape is littered with also-rans and a few major winners. Is Antares Pharma performing well enough for you? Read "Discover the Next Rule-Breaking Multibagger" to learn about a company Fool co-founder David Gardner believes will deliver amazing returns during the next few years. Click here for instant access to this free report.
- Add Antares Pharma to My Watchlist.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
Why Antares Pharma Inc Plummeted Today
An FDA rejection is coming for the drugmaker's testosterone replacement therapy Xyosted.
Why Shares in Antares Pharma, Inc. Burst Today
Antares Pharma, Inc. shares tumbled after it priced its secondary stock offering.
3 Stocks Crushed by the Market This Week
Find out which health-care stocks got beaten down the most by the market over the past few days.